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Background: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for development of
dyslipidemia. Continuous positive airway pressure (CPAP) is the ﬁrst-line treatment for OSAS. However, it
is unclear whether CPAP improves lipid metabolism.
Objectives: To review the effect of CPAP on lipid proﬁle of patients with OSAS.
Methods: We searched PubMed, Embase, and the Cochrane Library to identify eligible articles published
prior to October 30, 2013. Six randomized controlled trials (RCTs) were subjected to meta-analysis using
Comprehensive Meta-Analysis software.
Results: Six RCTs meeting the inclusion criteria were enrolled. The total numbers of measurements of
total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol, and high-density li-
poprotein (HDL) cholesterol, in CPAP intervention patients and sham/control groups, were 370 and 371,
330 and 328, 276 and 274, and 269 and 266 respectively. The pooled estimate of the difference in the
mean TC level between the CPAP and sham CPAP/control groups was signiﬁcantly different (0.15 [95%
conﬁdence interval, e0.27 to0.03]; p ¼ 0.01). Subgroup analysis revealed that OSAS patients of younger
age, who were more obese, and who had been treated via CPAP for a longer duration, showed a sig-
niﬁcant decrease in TC levels (the differences in the means were 0.27, 0.24, and 0.20; and the p
values 0.001, 0.01, and 0.04, respectively).
Conclusion: We conﬁrmed that CPAP decreases the TC level, especially in OSAS patients who are younger,
more obese, and who use CPAP for a longer period. CPAP did not alter TG, LDL, or HDL levels, suggesting
that CPAP may have no clinically important effect on lipid metabolism.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Obstructive sleep apnea syndrome (OSAS) is a common sleep
disorder, affecting about 24% of middle-aged males and 9% of
middle-aged females [1]. OSAS is characterized by repetitive epi-
sodes of partial or complete upper airway obstruction during sleep,
causing intermittent hypoxia, in turn triggering oxidative stress or
inﬂammation [2]. An increasing body of research shows that OSAS
is an independent risk factor for development of cardiovascular
events and morbidity, including dyslipidemia [3e5].
Continuous positive airway pressure (CPAP) therapy is the ﬁrst-
line treatment for OSAS [6]. The beneﬁts of CPAP include elimina-
tion of upper airway collapse, micro-arousals, and oxidative stress
during sleep; and improvement in clinical symptoms, including
snoring and excessive daytime sleepiness [7,8]. Previous studies
have shown that CPAP exerts a positive effect on metabolic syn-
drome [9]. In particular, the inﬂuence of CPAP on the levels of total
cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol, and triglyceride (TG), were
investigated [10e15].
Several articles exploring the beneﬁcial effects of CPAP treat-
ment on blood lipid levels have been published in the past few
years [10e16]. These include randomized controlled trials (RCTs),
original studies, and a review. However, few deﬁnite conclusions
can be drawn. Recently, three new RCTs exploring the effects of
CPAP on the blood lipid proﬁle have been conducted [12e14]. These
RCTs enrolled more OSAS subjects than did all prior studies com-
bined. It was thus necessary to systematically review and meta-
analyze all relevant RCTs to explore the effects of CPAP therapy
on lipid proﬁle.2. Materials and methods
We strictly followed the guidelines of PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analysis) [17].
Our registration number is CRD42013005732.2.1. Search strategy and selection of trails
We systematically searched PubMed, Embase, and the Cochrane
library. All pre-September 2013 literature examining the effects of
CPAP on blood lipid proﬁles was included. No language or other
restriction was imposed. The search terms used were: (Continuous
positive airway pressure or CPAP) and (obstructive sleep apnea or
OSA) combined with (lipids or lipid proﬁle or metabolic proﬁle or
dyslipidemia or cholesterol or TC or triglycerides or TG or HDL or
LDL). In addition, we manually searched for relevant published
studies and review articles.
We selected RCTs that met the following inclusion criteria: (1)
only adults (aged  18 years) with newly diagnosed OSAS were
studied; (2) CPAPwas applied; (3) the duration of CPAP therapywas
2 weeks; and, (4) the level of at least one of TC, TG, LDL, or HDL
was measured both before and after application of CPAP. Reviews,
abstracts, case reports, letters, and non-human studies were
excluded. Other exclusion criteria were: (1) treatment ofadolescents (age < 18 years); (2) diagnosis of OSAS in a manner
other than by determination of the AHI (AHI  5) or the oxygen
desaturation index (ODI) (ODI  7.5); (3) failure to record lipid
levels both before and after CPAP therapy, or the inadequacy of
supplied information in terms of allowing such values to be esti-
mated; and/or, (4) a duration of therapy of less than 2 weeks. Two
investigators (Drs. Xu and Guan) screened all relevant published
material using the abovementioned criteria. If disagreement arose,
a third reviewer (Prof. Yin) participated in resolution of the issue by
discussion.
2.2. Quality assessment
We evaluated the quality of each study with the Jadad score. The
Jadad score represents the quality of randomization, blinding,
withdrawal reporting, generation of random numbers, and alloca-
tion concealment. One point was allotted to each of these features,
and the score thus varied from 0 to 5 (the highest quality level).
Quality assessment was subjected to sensitivity analysis, because
low-quality trials may inﬂuence outcome measures. Quality was
independently assessed by two investigators (Drs. Xu and Guan).
2.3. Data extraction
Data were extracted from RCTs meeting the inclusion criteria.
These data were the ﬁrst author; year of publication; the country in
which the work was performed; study design; number of subjects;
sex, age, body mass index (BMI), and AHI or ODI values of the
participants; the duration of CPAP intervention; the extent of
adherence to CPAP; post-intervention TC, TG, LDL, HDL, weight,
BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP),
fasting glucose, and/or homeostasis model assessment of insulin
resistance (HOMA-IR) data from both the CPAP and the sham CPAP/
control groups; and the mean differences in the levels of TC, TG,
LDL, HDL, and weight, BMI, SBP, DBP, fasting glucose, HOMA-IR
between the test and control groups. Our ﬁnal analysis featured
examination of these differences and the associated conﬁdence
interval (CI). The differences were calculated if not directly
provided.
2.4. Quantitative data synthesis
Data on differences in TC, TG, LDL, HDL levels, and weight, BMI,
SBP, DBP, fasting glucose, and HOMA-IR between the two groups
were analyzed using pooled estimates of the differences in means,
and the associated CIs were calculated. Funnel plots of standard
errors and differences in means were used to assess publication
bias. We also used Begg’s test and the Mazumdar rank correlation
approach to this end [18]. Heterogeneity was assessed with the aid
of the I-squared index. If a p value was <0.10, the existence of
statistical heterogeneity was suggested and the data were analyzed
using a random-effects model. Otherwise, the datawere considered
to be homogeneous and a ﬁxed model was employed. Compre-
hensive Meta Analysis software, version 2.2.064, was used to
analyze all data.
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3.1. Search results
One hundred and forty-two articles were initially identiﬁed by
electronic and manual searching. After review of the titles and
abstracts, 104 studies were excluded whereas 38 were considered
to be potentially relevant. Of these, 29 articles not met the re-
quirements were next excluded. A total of nine RCTs were consid-
ered worthy of additional analysis. Of these, one was subsequently
excluded because it dealt with postprandial lipidemia [19]; another
was excluded because randomization was used only to assign pa-
tients to early or late initiation of CPAP therapy, and no control/
sham group was included [20]; and a third study lacked sufﬁcient
information on lipid levels [21]. The detailed steps of our literature
search are shown in Fig. 1. Finally, six studies meeting the inclusion
criteria were included in the meta-analysis [10e15]. The total
numbers of measurements of total cholesterol (TC), triglyceride
(TG), low-density lipoprotein (LDL) cholesterol, and high-density
lipoprotein (HDL) cholesterol made in CPAP intervention patients
and sham/control groups were 370 and 371, 330 and 328, 276 and
274, and 269 and 266, respectively.
3.2. Characteristics of the studies
All eligible studies were published between 1991 and 2013.
Three studies were conducted in the United Kingdom [10,12,15],
one in Canada [11], one in Switzerland [13], and one in India [14]. Of
the six studies, three featured a crossover design [10,11,14] and the
other three a parallel design [12,13,15]. All participants were at least
30 years of age and had BMIs of 31 kg/m2 or more. The duration of
effective CPAP treatment was 2e24 weeks. Four studies deﬁned
OSAS as an AHI of 5 events per hour and all subjects had severe
OSAS [10,11,13,14]. The other two studies deﬁned OSAS as an ODI 142 references obtained from search 
according to key terms
The effects of CPAP on OSAS patients fo
meta-analysis: TC (n=6); TG (n=6); LDL
Article
No orig
Non R
Insuffi
RCTs r
RCTs s
Potential relevant references for further fu
RCTs finally included in the meta-analys
Fig. 1. Flow diagram of study selection process. 6, 6, 5 and 5 studies referring CPAP therap
samples for TC, TG, LDL, and HDL in CPAP intervention groups and sham/control groups w7.5 or 10 instances of oxygen desaturation of 4% or more per hour,
respectively [12,15]. CPAP nightly usage varied from 2.39 to
6.2  1.1 h. Five studies had Jadad scores 3 [10,12e15], and one
study scored only 1 [11]. Relevant features of all studies are shown
in Table 1.
3.3. Pooled lipid proﬁle analysis
The pooled estimates of differences in mean TC, TG, LDL, and
HDL levels between the CPAP and the sham CPAP/control groups
were0.15 [95% CI,0.27 to0.03; p¼ 0.01]; 0.00 [95% CI,0.11 to
0.11; p ¼ 0.96]; 0.04 [95% CI, 0.17 to 0.10; p ¼ 0.58] and 0.02
[95% CI, 0.07 to 0.02; p ¼ 0.26], respectively, indicating that CPAP
therapy lowered only the TC level (Fig. 2). The mean and standard
deviation data for TC, TG, LDL, and HDL are recalculated and sum-
marized in Table 2.
3.4. Pooled analysis on other metabolic syndrome components and
the anthropometric variables
Only two studies have reported weight and BMI data before and
after CPAP treatment [12,14]. Craig et al. found that the mean dif-
ference in BMI between CPAP and sham CPAP/control groups
increased (0.40 [95% CI, 0.10 to 0.70]; p ¼ 0.02) [12]. However,
Sharma et al. found that the difference in mean weight and BMI
between CPAP and sham CPAP/control groups decreased signiﬁ-
cantly (0.70 [95% CI, 1.40 to 0.03]; p ¼ 0.03); (0.29 [95%
CI, 0.51 to 0.06]; p < 0.01) [14]. No signiﬁcant difference was
observed in the pooled estimate of the difference in the mean BMI
between the CPAP and sham CPAP/control groups (0.096 [95%
CI, 0.11 to 0.30]; p ¼ 0.35).
Components of metabolic syndrome, including SBP [10,11,13,14],
DBP [10e14], fasting glucose [10e14], and HOMA-IR [10e14] were
pooled in this meta-analysis. We found that CPAP had a positiver intervention studies included in the 
(n=5); HDL (n=5)
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H. Xu et al. / Atherosclerosis 234 (2014) 446e453 449effect on the pooled SBP estimate, and that the difference in means
between the CPAP and sham CPAP/control groups was 2.236 (95%
CI: 3.314 to 1.158, p < 0.001). CPAP also improved DBP, and the
difference in means between the CPAP and sham CPAP/control
groups was1.640 (95% CI:2.342 to0.938, p< 0.001). However,
CPAP had no effect on fasting glucose (difference in means:0.004,
95% CI: 0.050 to 0.042, p ¼ 0.857) or HOMA-IR (difference in
means: 0.056, 95% CI: 0.125 to 0.238, p ¼ 0.543).
3.5. Subgroup lipid proﬁle analysis
Subgroup analysis of the TC data was performed after segrega-
tion by age (<50 years and 50 years); severity of obesity (BMI
<35 kg/m2 and 35 kg/m2); duration of intervention (<12 weeks
and 12 weeks); and nightly CPAP duration (<5 h and 5 h)
(Table 3). In younger (<50 years) patients, the pooled estimates of
the difference in the mean TC value signiﬁcantly decreased (0.27;
95% CI,0.42 to0.11; p¼ 0.001); however, this was not evident in
older (50 years) patients (0.02; 95% CI, 0.16 to 0.20; p ¼ 0.84). In
severely obese subjects, TC levels fell upon application of CPAP
(0.24; 95% CI, 0.41 to 0.06; p ¼ 0.01) but this was not the case
in obese subjects (0.08; 95% CI, 0.28 to 0.08; p ¼ 0.31). A longer
duration of CPAP application (12 weeks) caused a signiﬁcant
reduction in TC level (0.20, 95% CI, 0.40 to 0.01; p ¼ 0.04) but
this was not the case when the duration of CPAP application was
shorter (0.12; 95% CI, 0.27 to 0.03; p ¼ 0.11). The extent of
adherence to the CPAP protocol did not affect TC levels (0.18; 95%
CI, 0.39 to 0.02; p ¼ 0.08) and (0.14; 95% CI 0.28 to 0.01;
p ¼ 0.07), respectively (Table 2). Sensitivity analysis revealed that if
data from the lower quality study (Jadad score 3) were excluded,
the positive effect of CPAP intervention on TC levels remained
(0.22; 95% CI, 0.37 to 0.08; p ¼ 0.00). Subgroup analysis of TG,
LDL, and HDL data yielded no ﬁnding of interest (Table 3).
3.6. Heterogeneity and publication bias
We used the I-squared index to explore variability in effect-size
estimates among studies. The index values for the differences in
mean TC, LDL, and HDL values between tests and controls were
35.93, 0.00, and 0.00, respectively (p¼ 0.17; p¼ 0.45; and p¼ 0.66),
indicating that the studies were homogeneous in nature. However,
signiﬁcant heterogeneity in TG data was evident (65.016;
p ¼ 0.014). We excluded data from a report that used CPAP for only
2 weeks [13], and the I2 index of TG changed to 0.00 (p ¼ 0.852).
Funnel plots were not obviously asymmetric (picture not shown).
The Begg’s and Mazumdar rank correlation test did not suggest the
presence of publication bias (Table 4).
4. Discussion
We found that CPAP treatment of patients with OSAS lowered
metabolic dyslipidemia, as evidenced by the difference in mean TC
levels between the test and control groups; however, TG, LDL, and
HDL levels did not decrease. CPAP was more effective in younger
(<50 years) severely obese (BMI 35 kg/m2) patients when applied
for 12 weeks (Table 3). Our ﬁndings show that CPAP did not alter
TG, LDL, or HDL levels, suggesting that CPAP may have no clinically
important effect on lipid metabolism. CPAP lowered the SBP and
DBP of patients with OSAS. However, CPAP had no effect on BMI,
fasting glucose, or HOMA-IR.
Studies of the association between OSAS status and lipid proﬁle
have yielded conﬂicting results [16]. Some authors found that OSAS
was independently associated with abnormalities in lipid levels
[22e25], while others suggested that dyslipidemia was linked to
obesity and not to OSAS per se [26,27]. However, the cited studies
Fig. 2. Forest plots for differences in means and corresponding 95% conﬁdence intervals (CIs) in assessment of lipid proﬁle. The pooled estimate of the difference in means in TC, TG,
LDL, and HDL between the CPAP and the sham CPAP/control groups were (0.15[95%CI, 0.27 to 0.03]; p ¼ 0.01); (0.00[95%CI, 0.11 to 0.11]; p ¼ 0.96); (0.04[95%CI, 0.17 to
0.10]; p ¼ 0.58) and (0.02[95%CI, 0.07 to 0.02]; p ¼ 0.26) respectively. In Figure 2.1, 2.2, 2.3 and 2.4, A means CPAP intervention group; B means sham/control group.
H. Xu et al. / Atherosclerosis 234 (2014) 446e453450had small sample sizes and did not control for confounding factors.
Thus, the works did not directly explore the relationship between
OSAS and dyslipidemia. Interventional studies may potentially
reveal any causal relationship between OSAS and an abnormal lipid
proﬁle. CPAP is the ﬁrst accepted treatment for OSAS. Many non-
controlled trials claimed that CPAP treatment was of beneﬁt to
those with metabolic disorders [28e30]. However, other non-
controlled studies came to the opposite conclusion [31e33]. Thus,
the precise mechanism by which CPAP treatment affects the lipid
proﬁle remains incompletely understood. The RCT is the gold
standard for clinical trials. However, only a few relevant RCTs havebeen conducted, and the results differed [10e15]. Thus, a meta-
analysis is required to explore the possible relationship between
CPAP therapy and lipid proﬁles in patients with OSAS.
We found that only the TC level decreased in patients with OSAS.
Establishment of dyslipidemia in patients with OSAS is a long
process that is affected by several factors, including the OSAS
severity, nocturnal hypoxia, obesity, sympathetic activity, diet, and
exercise [15,22,23,34]. Thus, OSAS is just one of several risk factors
triggering dyslipidemia, and it is not surprising that not all lipid
levels were affected. TC is one of the ﬁrst components to respond to
the reduction in oxidative stress associated with OSAS treatment
Table 2
Outcome of lipid variables in individual studies included in the meta-analysis.
First author, year TC TG
Comp* CPAP* Comp* CPAP*
Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up
Coughlin, 2007 NR NR 5.7  0.1 5.5  0.1 NR NR 1.9  0.2 1.8  0.2
Comondore, 2009* 4.78  1.44 4.80  1.28 4.80  2.29 4.94  2.10 1.53  1.9 1.90  2.17 1.83  2.5 1.68  1.78
Craig, 2012 5.2  1.1 5.1  1.2 5.3  1.2 5.1  1.1 1.69  0.9 1.71  0.9 1.68  1.00 1.67  0.88
Kohler, 2011 5.1  1.44 4.9  1.28 4.8  2.29 4.8  2.10 1.7  1.06 1.5  1.39 1.2  0.55 1.4  0.78
Sharma, 2011 4.94  1.02 5.04  0.89 5.47  0.93 5.23  0.94 1.76  0.70 1.76  0.87 2.23  1.05 2.02  0.95
Robinson, 2004 5.7  1.1 5.63  1.13 5.6  1.3 5.32  1.01 2.6  1.9 2.55  2.17 3.3  2.5 3.06  1.78
First author, year LDL HDL
Comp* CPAP* Comp* CPAP*
Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up
Coughlin, 2007 NR NR 3.7  0.1 3.6  0.1 NR NR 1.1  0.1 1.1  0.1
Comondore, 2009* 2.91  1.44 2.85  1.25 2.84  1.32 2.92  1.00 1.10  0.38 1.14  0.34 1.15  0.44 1.12  0.40
Craig, 2012 3.09  1.0 2.99  1.1 3.18  0.99 3.07  0.97 1.28  0.32 1.26  0.33 1.32  0.39 1.28  0.35
Kohler, 2011 3.2  1.44 3.0  1.25 3.1  1.32 3.0  1.00 1.1  0.38 1.1  0.34 1.3  0.44 1.3  0.40
Sharma, 2011 3.03  0.80 3.13  0.71 3.32  0.76 3.17  0.73 1.08  0.17 1.08  0.28 1.14  0.15 1.14  0.29
Robinson, 2004 NR NR NR NR NR NR NR NR
Abbreviation: TC ¼ total cholesterol; TG ¼ total triglyceride; LDL ¼ low-density lipoprotein; HDL ¼ high-density lipoprotein; CPAP ¼ continuous positive airway pressure;
Comp ¼ comparator; NR ¼ not reported. Note: *no reported SD of weight change so assumed as SD of highest of rest of group.
H. Xu et al. / Atherosclerosis 234 (2014) 446e453 451[15]. Patients treated with CPAP altered their diets and increased
their levels of physical activity, eventually leading to a fall in TC
levels [15]. The fact that CPAP therapy enhances the sympathetic
response to hypoxic chemoreﬂex stimulation may also contribute
to the lowered serum TC level noted in OSAS patients [34,35].
Changes in weight affect blood pressure and glucose and lipid
metabolism. Improvements in blood pressure, glucose metabolism,
hypertriglyceridemia, and low HDL-C levels are observed after
weight loss [36]. Our ﬁndings show that CPAP decreased TC level,
SBP, and DBP of patients with OSAS but had no effect on BMI,
HOMA-IR, or metabolism of TG, LDL, HDL, or serum glucose. BMI as
well as metabolic syndrome componentsdsuch as fasting glucose
and HOMA-IRdare confounding factors in the correlation between
OSAS and serum lipids [37]. All studies included in our meta-
analysis were RCTs, which should consider matching confoundingTable 3
Results of subgroup and sensitivity analyses for evaluating the effect of CPAP usage on li
Variables TC TG
Mean difference (mmol/L) with 95%
Age
<50 years old 0.265(0.416e0.113) 0.13
P ¼ 0.001 P ¼ 0
>50 years old 0.020(0.164e0.203) 0.134
P ¼ 0.835 P ¼ 0
Weight of subjects
Obesity(BMI<35 kg/m2) 0.081(0.237e0.075) 0.083
P ¼ 0.310 P ¼ 0
Severe obesity(BMI > 35 kg/m2) 0.237(0.413e0.061) 0.11
P ¼ 0.008 P ¼ 0
Interventional duration
<12W 0.119(0.266e0.027) 0.050
P ¼ 0.110 P ¼ 0
>12W 0.203(0.398e0.009) 0.07
P ¼ 0.040 P ¼ 0
CPAP adherence
<5 h 0.178(0.387e0.022) 0.06
P ¼ 0.081 P ¼ 0
>5 h 0.135(0.279e0.009) 0.118
P ¼ 0.066 P ¼ 0
Sensitivity analyses
Excluding low quality studies (Jadad 3) 0.223(0.368e0.079) 0.021
P ¼ 0.002 P ¼ 0
Abbreviation: AHI ¼ apnea hypopnea index; BMI ¼ body mass index; CPAP ¼ continuous
density lipoprotein; HDL ¼ high-density lipoprotein.factors. Because our meta-analysis focused on the effect of CPAP on
lipids, only RCTs that included this subject were enrolled, and so the
pooled population was different from those in previous meta-
analyses designed speciﬁcally for the aforementioned factors.
Thus, the results of our meta-analysis may show little difference
from those of previous meta-analyses [38e40].
We performed subgroup analysis to identify the principal fac-
tors inﬂuencing lipid proﬁles. No changes in TG, LDL, or HDL levels
were evident in OSAS patients subdivided by age, BMI, nightly
duration of CPAP application, or overall duration of CPAP therapy.
However, the TC levels fell signiﬁcantly in younger, more obese
patients treated with CPAP for longer periods. Particularly, CPAP
therapy sharply decreased the TC level in younger patients (<50
years). We speculate that dyslipidemia in younger patients is mild
and reversible, but severe and irreversible in older patients. CPAPpid proﬁle.
LDL HDL
conﬁdence intervals and P value
5(0.290e0.021) 0.235(0.494e0.024) 0.051(0.147e0.045)
.089 P ¼ 0.075 P ¼ 0.297
(0.018e0.286) 0.036(0.123e0.195) 0.018(0.064e0.028)
.084 P ¼ 0.656 P ¼ 0.449
(0.057e0.223) 0.037(0.173e0.100) 0.016(0.060e0.028)
.247 P ¼ 0.601 P ¼ 0.475
8(0.289e0.054) 0.100(1.009e0.809) 0.100(0.234e0.034)
.179 P ¼ 0.829 P ¼ 0.143
(0.089e0.190) 0.095(0.152e0.343) 0.030(0.084e0.024)
.478 P ¼ 0.450 P ¼ 0.275
1(0.224e0.102) 0.095(0.256e0.067) 0.015(0.081e0.050)
.422 P ¼ 0.250 P ¼ 0.646
6(0.203e0.071) 0.014(0.211e0.183) 0.039(0.104e0.026)
.346 P ¼ 0.887 P ¼ 0.241
(0.060e0.295) 0.059(0.246e0.127) 0.014(0.068e0.040)
.194 P ¼ 0.534 P ¼ 0.618
(0.110e0.152) 0.093(0.290e0.103) 0.017(0.072e0.038)
.751 P ¼ 0.353 P ¼ 0.549
positive airway pressure; TC ¼ total cholesterol; TG ¼ total triglyceride; LDL ¼ low-
Table 4
Kendall’s tau b (corrected for ties, if any) with one-tailed or two-tailed P value (based
on continuity-corrected normal approximation).
TC TG LDL HDL
Kendall’s tau b 0.13 0.13 0.00 0.30
Kendall’s tau b with a one-tailed P value 0.35 0.35 0.50 0.73
Kendall’s tau b with a two-tailed P value 0.71 0.71 1.00 0.46
H. Xu et al. / Atherosclerosis 234 (2014) 446e453452therapy had a more obvious effect on the TC level of severely obese
patients (BMI > 35 kg/m2) compared to obese subjects (BMI 30e
35 kg/m2). OSAS is always associated with obesity, and adiposity is
a confounding risk factor for metabolic dyslipidemia [41]. Inﬂam-
matory marker levels in OSAS patients rise as obesity becomes
more pronounced [42,43]. Meta-analysis revealed that CPAP ther-
apy could partially suppress systemic inﬂammation in OSAS pa-
tients [44]. CPAP applicationmay also directly reduce fat levels [14].
This may explain why the TC level decreased signiﬁcantly in
severely obese patients. CPAP therapy had a more obvious effect on
TC level when such therapy was of long duration. This may be
because an elevated blood lipid level in OSAS patients is a chronic
condition. The total number of patients in our meta-analysis was
small (230e250 per group), and smaller when we performed the
subgroup analysis. Thus, the lack of statistical signiﬁcance in TG,
LDL, and HDL levels in the subgroup analysis may be due to the
small group sizes.
To our knowledge, this is the ﬁrst meta-analysis to investigate
the effects of CPAP treatment, administered in the course of RCTs,
on lipid proﬁle, and our work has some advantages. First, pooling of
information from all eligible RCTs yielded results that these were
more precise and reliable than the results of individual studies.
Second, no signiﬁcant heterogeneity was evident among the
included studies. Third, the funnel plots did not reveal any publi-
cation bias. Finally, patient age, BMI, duration of CPAP intervention,
and extent of nightly CPAP usage were comparable among the
studies.
Our study had some limitations. First, few RCTs have addressed
the topic of interest, and the total sample size was relatively small.
Additional large-scale well- designed RCTs featuring good adher-
ence to therapy and long-term follow-up are required. Second,
negative results may not have been published, creating publication
bias. Third, the duration of CPAP therapy (2e24 weeks) was rela-
tively short, and may have been inadequate to change lipid proﬁles.
Fourth, physical activity and consumption of a high-fat diet can
affect serum lipid levels independently of OSAS [45]. Finally, RCTs
evaluating long-term CPAP intervention face an ethical problem,
because long-time sham CPAP treatment may have serious conse-
quences for OSAS patients [46]. Thus, future RCTs with larger pa-
tient samples and longer follow-up durations remain challenging.
In conclusion, we found that application of CPAP signiﬁcantly
reduced the TC level, especially in younger, more obese patients,
and was associated with longer duration of CPAP application. This
was not true of the levels of TG, LDL, or HDL.Conﬂict of interest statement
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